艾滋病毒耐药性对撒哈拉以南非洲地区与艾滋病毒/艾滋病相关的死亡率、新感染率及抗逆转录病毒治疗项目成本的影响
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.
作者信息
Phillips Andrew N, Stover John, Cambiano Valentina, Nakagawa Fumiyo, Jordan Michael R, Pillay Deenan, Doherty Meg, Revill Paul, Bertagnolio Silvia
机构信息
Institute for Global Health, University College London, United Kingdom.
Avenir Health, Glastonbury, Connecticut.
出版信息
J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089.
Abstract
To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub-Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016-2030 will be attributable to HIVDR.
摘要
为了告知抗逆转录病毒治疗（ART）项目对HIV耐药性（HIVDR）应给予的关注程度，我们使用了一个个体水平模型来估计其在一系列项目情况下对撒哈拉以南非洲（SSA）未来艾滋病死亡、HIV发病率和ART项目成本的影响。我们通过Spectrum-Goals模型将其应用于SSA。在治疗前HIVDR当前水平超过10%（平均为15%）的情况下，2016年至2030年SSA地区16%的艾滋病死亡（89万例死亡）、9%的新感染（45万例）以及8%（65亿美元）的ART项目成本将归因于HIVDR。
相似文献
1
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.
J Infect Dis. 2017 May 1;215(9):1362-1365. doi: 10.1093/infdis/jix089.
2
Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
Clin Infect Dis. 2015 Dec 1;61(11):1749-58. doi: 10.1093/cid/civ656. Epub 2015 Aug 3.
3
Evaluation of treatment response, drug resistance and HIV-1 variability among adolescents on first- and second-line antiretroviral therapy: a study protocol for a prospective observational study in the centre region of Cameroon (EDCTP READY-study).
BMC Pediatr. 2019 Jul 5;19(1):226. doi: 10.1186/s12887-019-1599-z.
4
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.
5
The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates.
HIV Clin Trials. 2017 Jul;18(4):149-155. doi: 10.1080/15284336.2017.1349028. Epub 2017 Jul 18.
6
Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.
Lancet HIV. 2020 Sep;7(9):e629-e640. doi: 10.1016/S2352-3018(20)30211-3. Epub 2020 Aug 6.
7
The association between HIV pretreatment drug resistance and virological outcomes in children and adults in sub-Saharan Africa: A systematic review and meta-analysis.
PLoS One. 2024 Apr 16;19(4):e0300456. doi: 10.1371/journal.pone.0300456. eCollection 2024.
8
Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.
AIDS. 2013 Nov 28;27(18):2943-51. doi: 10.1097/01.aids.0000433237.63560.20.
9
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.
10
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa.
Lancet. 2000 Jun 17;355(9221):2095-100. doi: 10.1016/S0140-6736(00)02375-8.
引用本文的文献
1
HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024.
Open Forum Infect Dis. 2025 Aug 4;12(8):ofaf446. doi: 10.1093/ofid/ofaf446. eCollection 2025 Aug.
2
HIV-1 Drug Resistance in Children and Implications for Pediatric Treatment Strategies: A Systematic Review and Meta-analysis.
Open Forum Infect Dis. 2025 Jun 26;12(7):ofaf378. doi: 10.1093/ofid/ofaf378. eCollection 2025 Jul.
3
Antimicrobial resistance with a focus on antibacterial, antifungal, antimalarial, and antiviral drugs resistance, its threat, global priority pathogens, prevention, and control strategies: a review.
Ther Adv Infect Dis. 2025 May 23;12:20499361251340144. doi: 10.1177/20499361251340144. eCollection 2025 Jan-Dec.
4
Noncanonical HIV drug resistance mutations: need to close existing gaps.
AIDS. 2025 Jun 1;39(7):781-787. doi: 10.1097/QAD.0000000000004170. Epub 2025 Mar 17.
5
Pretreatment and acquired HIV drug resistance in Belize-results of nationally representative surveys, 2021-22.
J Antimicrob Chemother. 2025 Jan 3;80(1):292-300. doi: 10.1093/jac/dkae408.
6
[Analysis of HIV-1 Subtypes and Transmitted Drug Resistance in Hospitalized Treatment-Native Patients With AIDS].
Sichuan Da Xue Xue Bao Yi Xue Ban. 2024 Sep 20;55(5):1295-1300. doi: 10.12182/20240960209.
7
Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis.
EClinicalMedicine. 2024 Oct 4;77:102859. doi: 10.1016/j.eclinm.2024.102859. eCollection 2024 Nov.
8
Population dynamics of HIV drug resistance during treatment scale-up in Uganda: a population-based longitudinal study.
medRxiv. 2024 Oct 9:2023.10.14.23297021. doi: 10.1101/2023.10.14.23297021.
9
MARVEL-minimising the emergence and dissemination of HIV-1 drug resistance in Portuguese-speaking African Countries (PALOP): low-cost portable NGS platform for HIV-1 surveillance in Africa.
BMC Infect Dis. 2024 Aug 29;24(1):884. doi: 10.1186/s12879-024-09803-1.
10
HIV-1 Drug Resistance Detected by Next-Generation Sequencing among ART-Naïve Individuals: A Systematic Review and Meta-Analysis.
Viruses. 2024 Feb 2;16(2):239. doi: 10.3390/v16020239.
本文引用的文献
1
What Is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach.
PLoS One. 2016 May 9;11(5):e0154893. doi: 10.1371/journal.pone.0154893. eCollection 2016.
2
Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance.
J Antimicrob Chemother. 2016 May;71(5):1361-6. doi: 10.1093/jac/dkv500. Epub 2016 Feb 29.
3
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.
Lancet HIV. 2014 Nov;1(2):e85-93. doi: 10.1016/S2352-3018(14)70021-9. Epub 2014 Oct 14.
4
Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.
AIDS. 2014 Jan;28 Suppl 1:S15-23. doi: 10.1097/QAD.0000000000000082.
5
Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study.
AIDS. 2014 Jan 2;28(1):73-83. doi: 10.1097/01.aids.0000433239.01611.52.
6
HIV-1 genetic diversity and transmitted drug resistance mutations among patients from the North, Central and South regions of Angola.
PLoS One. 2012;7(8):e42996. doi: 10.1371/journal.pone.0042996. Epub 2012 Aug 29.
7
Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.
Lancet. 2012 Oct 6;380(9849):1250-8. doi: 10.1016/S0140-6736(12)61038-1. Epub 2012 Jul 23.
8
Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.
Lancet Infect Dis. 2012 Apr;12(4):307-17. doi: 10.1016/S1473-3099(11)70255-9. Epub 2011 Oct 27.
9
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.
Lancet Infect Dis. 2011 May;11(5):363-71. doi: 10.1016/S1473-3099(11)70032-9. Epub 2011 Feb 25.
Zotero 插件